stockrowGenmab A/S Sponsored ADR
GMAB Healthcare Biotechnology
Genmab A/S Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 19.2% from fiscal 2024.
- Revenue
- +24.9%
- EPS
- −9.26%
- Free cash flow
- −7.69%
Quarter to June 2026, against a year earlier
Follow GMAB
Alert me
Genmab A/S Sponsored ADR (GMAB) Total debt
Genmab A/S Sponsored ADR's total debt at the end of fiscal 2025 was $5.3B, up 6,057.4% from $85.7M in fiscal 2022. At the end of the quarter to 30 June 2026 it was $5.1B. Over the past ten years it has ranged from $27.2M (fiscal 2019) to $5.3B (fiscal 2025) — the current reading is the highest in ten years. Genmab A/S Sponsored ADR ranks 3rd of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $5.3B | 6,057.42% |
| FY2022 | $85.7M | 32.41% |
| FY2021 | $64.7M | 22.89% |
| FY2020 | $52.6M | 93.40% |
| FY2019 | $27.2M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $5.1B | (1.40%) |
| Mar 2026 | $5.2B | (1.25%) |
| Dec 2025 | $5.3B | 4,582.09% |
| Sep 2023 | $112.6M | (3.91%) |
| 17 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| RPRX Royalty Pharma PLC compare | $8.6B |
| GMAB Genmab A/S Sponsored ADR | $5.1B |
| RVMD Revolution Medicines, Inc. compare | $1.0B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $1.0B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $825.2M |
| INSM Insmed, Inc. compare | $562.8M |
| BNTX BioNTech SE Sponsored ADR compare | $414.1M |
| ROIV Roivant Sciences Ltd. compare | $323.7M |
| INCY Incyte Corporation compare | $27.6M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on GMAB
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement